NVS wins CHMP backing for remibrutinib in chronic spontaneous urticaria, bringing its oral BTK inhibitor closer to EU approval.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive ...

Overall, the CUPID-C trial corroborates earlier evidence that dupilumab can meaningfully reduce itch and hives in ...

Medically reviewed by Casey Gallagher, MD CSU is a skin condition that causes hives and swelling lasting six weeks or more.The cause of the condition is often unknown, but in the majority of cases ...

Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.

Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients ...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled ...

Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with ...

Even though it happened about 15 years ago, I’ll never forget when the hives started to develop. I was working the midnight shift as a nurse, and sleeping during the day. It didn’t seem like a big ...